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 ABSTRACT 
Cancer remains one of the leading causes of death worldwide. Modern treatments such as 
immunotherapy and neoadjuvant chemotherapy exhibit promising results. However better 
understanding of the treatments may lead to optimizations and consequently better prognosis.  
In this thesis, we begin to categorize subpopulations of B cells in patients with malignancies. 
We demonstrate increased proportions of plasmablasts, switched memory and CD86+ B cells 
in tumor associated tissues. Noticeable skewing of Igλ/Igκ ratio of tumor infiltrating B 
lymphocytes (TIL-Bs) indicates tumor specific B cell expansion. Monoclonal expansion is 
confirmed by spectrartype analysis and sequencing the clonally expanded heavy chain, 
reveals somatic hypermutation. We conclude that B cells in cancer patients, display signs of 
CD4+ T cell dependent response against cancer.  
Furthermore, we investigate the effect of three conventional chemotherapeutic drugs on 
human B cells. We expose increased CD86 expression on B cells upon doxorubicin treatment 
which explains their escalated antigen presenting ability. In addition, doxorubicin results in 
decreased production of the cytokines, IL-10 and TNF-α. Investigation of B cells in urinary 
bladder cancer patients treated with neoadjuvant chemotherapy containing doxorubicin, 
reveals increased CD86 expression. Thus we argue, optimization of time and dose schedules 
may increase the potency of a chemotherapy and immunotherapy combination.  
TILs have increasingly been correlated with patient survival. TIL-Bs are reportedly a 
significant part of TILs. We illustrate that urinary bladder cancer patients, exhibit tumor 
associated follicular-like structures (FLSs) in the proximity of tumor where B cells and T 
cells interact. We demonstrate that FLSs and tumor-associated CD38+ plasma cells, in 
addition to IL-10 produced by non-B cells, may contribute to positive patient prognoses. On 
the contrary, IL-10 produced by tumor-associated Bregs, may affect the prognosis negatively.  
It is acknowledged that B cells undergo allelic exclusion. On the contrary to this 
understanding, we describe rare Igλ+ Igκ+ B cell populations in cancer patients which are 
increased in tumor associated tissues and present in activated B cell populations, as well as 
among switched memory B lymphocytes. Furthermore we demonstrate that they do not 
undergo somatic hypermutation and receptor editing. We conclude their emergence is due to 
the influence of tumor environment which is confirmed by Igλ+ Igκ+ B cell induction in 
culture with supernatant from a tumor cell line.  
Due to highly specific antigen receptors, B cells may be very effective antigen presenting 
cells (APCs). Further studies can reveal their role as APCs in cancer patients which may be 
exploited for CD4+ T cell adoptive immunotherapy.  
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 1 INTRODUCTION 
Immunology is a relatively new science compared to other scientific fields. It is believed to 
originate from Edward Jenner who discovered the vaccine against smallpox in 1796. Later, 
scientists from the 19th century such as Robert Koch and Louise Pasteur continued with the 
field by proving that infectious disease was caused by microorganisms and by developing 
rabies vaccine respectively. The immune system comprises of molecules, cells and organs, 
which recognize and help clearing potential threats. It is divided into evolutionarily indigenous 
innate immune system which provides immediate defense against a pathogen and specialized, 
long lasting adaptive immune system, which is developed during lifetime of an individual and 
divides into humoral and cell-mediated immunity.  
All the cells of the immune system originate from hematopoietic stem cells in the bone marrow. 
The progenitor of the innate immune cells, myeloid progenitors, enter the blood from the bone 
marrow and when needed, migrate to infected or damaged tissues before they differentiate into 
dendritic cells, macrophages, mast cells, etc. Organized tissues containing cells of the adaptive 
immune system comprise of central lymphoid organs, such as bone marrow and thymus where 
the cells are generated, and peripheral lymphoid organs, such as blood, lymph nodes and spleen 
where the cells of the adaptive immune system, the lymphocytes, reside and where the adaptive 
immune response is initiated.  
Tumors are recognized and rejected by the immune system with the help of expressed tumor 
antigens on the surface of tumor cells. There are multiple types of tumor antigens to be named, 
including point mutated oncogenes or tumor suppressors such as Caspase-8 (Kim, Lee et al. 
2003, Fulda 2009), proteins which are normally expressed only in male germline cells, MAGE-
1 and 3 (Boon, Coulie et al. 1997), and antigens only expressed in specific tissues, such as 
enzymes involved in synthesis of black pigment, melanin. In addition, over expression of self-
antigens in tumors compared to non-malignant cells, such as Her-2/neu (Slamon, Godolphin et 
al. 1989), proteins that exhibit abnormal posttranslational modifications e.g. MUC-
1(Hollingsworth and Swanson 2004), and oncoviral antigens, such as the human 
papillomavirus (HPV) type 16 proteins, E6 and E7 have been detected(Walboomers, Jacobs et 
al. 1999). However, successful tumors in cancer patients use multiple mechanisms by which 
they can escape the immune system and survive. 
This thesis investigates B cell responses in cancer patients (papers I and III) as well as the effect 
of the tumor environment on rare subtype of B cells, Ig κ+ Ig λ+ CD19+ cell (paper IV). In 
addition, it reflects on the influence of chemotherapy on B cells and their ability to enhance T 
cell responses (paper II).  
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 1.1 ADAPTIVE IMMUNE RESPONSE 
The adaptive immune response comprises of mainly B and T cells, both of which originate in 
the bone marrow. However, T cell progenitors leave the bone marrow to reside in the thymus 
and continue with their full development into naïve T cells whereas B cell development occurs 
in the bone marrow. Several T cell subsets have been described which develop into effector 
cells and have distinct functional properties. Two major subsets are CD4+ and CD8+ T cells. 
Naïve CD4+ T cells develop into T helper cells and orchestrate different immune cell responses 
by producing cytokines, whereas naïve CD8+ T cells develop into cytotoxic T lymphocytes 
(CTL) which can directly eliminate infected cells and tumor cells. B cells produce antibodies 
and contribute to the humoral immune response. In addition, both T and B lymphocytes are 
necessary for the development of long-term immunological memory. 
Naïve CD4+ T cells require interaction with antigen presenting cells (APCs) to get activated 
and function as T helper cells. They recognize foreign and mutated self-antigens as peptides in 
the context of MHC class II molecules, displayed by professional APCs (Ashwell, DeFranco 
et al. 1984). 
1.2 ANTIGEN PRESENTING CELLS 
There are three distinct classes of professional APCs, namely macrophages, dendritic cells and 
B cells (Ashwell, DeFranco et al. 1984). Upon encountering an antigen, they internalize it by 
endocytosis or in the case of B cells by receptor-mediated endocytosis (Figure 1). Endosomes 
containing the antigen, acidify as they travel inside the cell and fuse with lysosomes. 
Acidification activates proteases inside the vesicles, which in turn can degrade the antigens into 
smaller peptide fragments. The vesicles containing peptide fragments fuse with vesicles 
containing MHC class II molecules where peptides bind to the MHC class II pockets and are 
brought up to the surface of the APCs for presentation to T cells. Upon encountering a peptide 
specific CD4+ T cell, there are three signals needed for both cells to be fully activated. The first 
signal is the specific binding of the T cell receptor with MHC class II-antigen complex, after 
which several costimulatory molecules on both cells are upregulated. The second signal is 
binding of the costimulatory molecules on both cells. CD86 expressed on APCs bind to CD28 
on T cells whereas CD40 on APCs bind to CD40 ligand (CD40L) on T cells which contributes 
to further activation. Finally, production and secretion of inflammatory cytokines, such as 
interleukin 2 (IL-2), interferon gamma (IFN-γ) or IL-4 leads to binding of the cytokines to their 
respective receptors on the cells and hence the third signal and full cell activation (Jenkins, 
Khoruts et al. 2001).  
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1.3 B LYMPHOCYTES 
1.3.1 Development 
B cell progenitors reside and develop in the bone marrow from hematopoietic cells. Their 
development involves receptor gene rearrangements, which is defined into three developmental 
stages (Carsetti, Rosado et al. 2004). In the first stage, pro-B cells go through D and J 
recombination of the heavy chain (H-chain), which is then followed by rearranging the V 
region to join the previously recombined DJ segment. The next step is to rearrange the μ-H-
chain. A complete heavy chain is then fused with the surrogate light chains which consist of 
two proteins, λ5 and VpreB. Together they form the pre-B cell receptor. If a functional receptor 
is achieved, the cell enters the second stage of the B cell development, the pre-B cell stage. It 
 Figure 1. Schematic overview of a B cell antigen presentation. After encountering 
antigen via BCR, the B cell internalize it, process it and present it to T cells using MHC 
class II. Three signals contribute to full activation of both B and T cells; 1. MHC class 
II-peptide interaction with T cell receptor (TCR) complex. 2. Costimulatory binding on 
both cells. 3. Cytokine secretion. Figure courtesy of Malin Winerdal.  
 
 3 
 is in this stage when light chain rearrangements occur. The heavy and light chain recombination 
of the variable regions at this stage, occur when two recombination activating gene (RAG) 1 
and 2 complexes, bind to the conserved recombination signal sequences (RSSs) which exist on 
the flanks of the gene segments. RAG complexes then cleave the DNA with their endonuclease 
activity. At this stage, DNA repair enzymes begin to modify the open ends of the DNA 
segments, removing nucleotides by exonuclease activity and adding random new nucleotides, 
using the enzyme, terminal deoxynucleotidyl transferase (TdT). Finally DNA ligase IV joins 
the modified open DNA strands together, reconstructing new rearranged gene (Schlissel 2003).  
In the third stage, Combination of a μ chain and either a κ or λ light chain gives rise to an IgM 
molecule, which is expressed, on the cell surface, creating a massive repertoire of B cells with 
>1014 different antigen specificities (Yaari and Kleinstein 2015). At this stage, the cells are 
designated immature B cells. B cells with non-functional or autoreactive receptors, which do 
not survive the bone marrow, are deleted (Spanopoulou, Roman et al. 1994) and only positively 
selected B cells leave the bone marrow as transitional B cells (CD38hi IgMhi) to enter the spleen 
and complete their development to mature naïve B cells. It has been reported in a study with 
mice that only 10-20% of the immature B cells reach the spleen (Rolink, Andersson et al. 1998). 
1.3.2 Receptor editing 
B cell progenitors, which produce non-functional, or autoreactive receptors in the bone 
marrow, can rearrange their receptor gene segments in an attempt to make their receptors more 
functional or less self-reactive and thus evade apoptosis. After a functional heavy chain is 
expressed, the light chain segments are set to be tested in order (Korsmeyer, Hieter et al. 1982). 
Firstly, Ig κ light chain RAG dependent rearrangement on one allele occurs. If a functional 
receptor is not achieved, new rearrangements on the second allele is tested. In case of failure, 
Ig λ light chain on one allele and then again on the second allele is tried. Final outcome of a B 
cell with a functional receptor leads to downregulation of further receptor rearrangements 
leading to survival of the B cell with one single receptor in a process called allelic exclusion.  
However, in violation of allelic exclusion, B cells with dual Ig κ and Ig λ light chain have been 
encountered in different studies (Giachino, Padovan et al. 1995, Xu 2006). In a study with anti-
DNA heavy chain transgenic mice, Ig κ+ Ig λ+ B cells were detected in the marginal zone and 
were revealed to be partially autoreactive (Li, Jiang et al. 2001, Li, Li et al. 2002). In addition 
dual light chain positive B cells have been observed in a patient with chronic lymphatic 
leukemia (CLL) (del Senno, Gandini et al. 1987). Ig κ+ Ig λ+ B cells have essentially been 
studied in mice and in patients with malignant B cells. Relatively, little is known about B cells 
with dual positive light chains in patients with solid tumors.  
1.3.3 B cell subsets 
The phenotype of naïve B cell subsets has been described in different studies. According to the 
Freiburg classification, they express IgM and IgD but lack the tumor necrosis factor (TNF) 
receptor superfamily molecule, CD27 (Figure 2) (Wehr, Kivioja et al. 2008). Upon activation 
B cells upregulate the early activation marker CD69 (Hara, Jung et al. 1986) followed by the 
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 costimulatory molecules CD80 and CD86 (Hathcock, Laszlo et al. 1994). Activated B cells 
enter germinal centers around day 3-5 after T cell dependent activation (Liu, Johnson et al. 
1992). In germinal centers B cells go through class switch recombination (CSR), somatic hyper 
mutation (SHM) and clonal expansion (MacLennan 1994). CSR and SHM are initiated by 
activation-induced cytidine deaminase (AID), which converts the cytidine base (C) into uracil 
(U) by deamination of the former base. During DNA replication, U is converted to thymine (T) 
which then leads to an overall gene conversion from C:G to T:A (Petersen-Mahrt, Harris et al. 
2002, Peled, Kuang et al. 2008, Stavnezer 2011).  
Additional T cell signals, such as CD40 ligand (CD40L) can contribute to the survival of B 
cells and allow them to develop into memory B cells (IgD- CD27+), whereas the cytokines IL-
10 and IL-2 can cause differentiation into class switched plasmablasts (CD38+++ IgM-) and later 
antibody secreting plasma cells (Figure 2) (Arpin, Dechanet et al. 1995, Liu and Banchereau 
1997). Plasma cells travel to the site of infection or return to the bone marrow and produce 
antigen specific antibodies. 
 
 
 
 
Figure 2. Subtypes of B cells. Transtional B cells enter the 
periphery from the bone marrow to reside in the spleen and 
mature to naïve B cells. Upon antigen encounter and T cell 
interaction, followed by clonal expansion in the germinal center, 
they can either differentiate to switched memory B cells or to 
plasmablasts and finally antibody secreting plasma cells. 
Marginal zone-like (MZ) and CD21low B cells have also been 
detected in human. MZ express IgM and exhibit memory B cell 
properties. CD21low also express IgM but show signs of previous 
activation. Figure courtesy of Malin Winerdal. 
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 In addition to the mentioned B cell sub-classes, another subtype, marginal zone (MZ) B cells 
(IgM+ IgD+ CD27+) can be noticed (Figure 2). They are IgM producing (CD27+ IgD+) B cells 
that in mice reside in marginal zone of the spleen. There are distinct differences between murine 
and human MZ B cells. Unlike in mice, human MZ circulate in the body and in addition to 
blood and spleen, they have been encountered in lymph nodes, tonsils and under the dome 
epithelium of Peyer’s patches in gut-associated lymphoid tissues (GALT) (Stein, Bonk et al. 
1980, Spencer, Finn et al. 1985, Liu, Barthelemy et al. 1995, Spencer, Perry et al. 1998, Dono, 
Zupo et al. 2000). Furthermore, the presence of somatic mutations in the IgM receptors of 
human MZ B cells, as opposed to their counterparts in rodents (Dammers, Visser et al. 2000), 
have prompted authors to call them marginal zone-like or IgM memory B cells. In general, MZ 
B cells are described to develop and respond to antigen, in a T cell-, germinal center-
independent manner (Weller, Braun et al. 2004).  
CD21low B cells have been encountered in patients with common variable immunodeficiency 
(Wehr, Kivioja et al. 2008). Their origin and function has been debated. Some studies describe 
it to resemble innate-like tissue homing B cells and suggest they exhibit previous activation 
and proliferation but are unable to proliferate in response to B cell receptor stimulation 
(Rakhmanov, Keller et al. 2009). Their role depends on the underlying condition.  
1.3.4 B cell receptor isotypes 
In general interaction between CD40 and CD40L on B and T cells respectively, generate class 
switching. The IgM receptor of naïve B cells is then switched to the isotypes, IgG, IgA or IgE, 
depending on the environment and location in the body. Each isotype is characterized by a 
distinct function. IgG is the most abundant isotype in human serum. It has been demonstrated 
to be induced by Interleukin-6 (IL-6) (IgG1) and a combination of IL-6 and IFN-γ (IgG2) 
(Kawano, Noma et al. 1994). IgA is mostly produced by B cells residing in intestinal and 
urogenital tracts. IgA in the mucosal secretion is found as dimers and oligomers in both mice 
and humans whereas circulating IgA antibodies exist predominantly as monomers in humans 
and largely as polymers in mice (Macpherson, McCoy et al. 2008). IgA class switching is 
induced by tumor growth factor beta (TGF-β) as well as a combination of CD40L, IL-4, IL-6 
and IL-10. The effector function of IgA is to bind to type I Fc receptor for IgA (FcαRI) 
expressed on innate immune cells, such as monocytes, macrophages, dendritic cells and 
granulocytes. In addition, IgA neutralizes toxins and pathogens in the mucosa (Cerutti, Zan et 
al. 1998, Cerutti 2008). IgE antibodies are associated with allergic reactions and asthma but are 
also involved in defense mechanisms against parasitic infections. The class switching 
recombination is induced by CD40L, IL-4 and IL-13 (Geha, Jabara et al. 2003). IgE is mainly 
produced under the skin or epithelial surfaces of the airways.  
1.3.5 Cytokines 
1.3.5.1 IL-2 
IL-2 is a cytokine with effects on many different cells, the most pronounced of which is the T 
cell. T cells synthesize IL-2 upon activation through their antigen peptide receptor, which is 
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 then followed by upregulation of the high affinity IL-2 receptor (CD25). Thus, IL-2 allows T 
cell to undergo rapid, specific expansion (Lenardo, Chan et al. 1999, Gaffen and Liu 2004) and 
it is also needed for their long-term survival (Rathmell, Vander Heiden et al. 2000, Frauwirth 
and Thompson 2004). Additionally, IL-2 can promote upregulation of IL-2 receptor on B cells 
and consequently induce differentiation to plasma cells (Miyawaki, Suzuki et al. 1987).  
In addition to activated CD4+ T cells and B cells, regulatory CD4+ CD25+ T cells (Tregs) also 
express CD25, which is a subunit of the IL-2 receptor, but the latter produce the molecule in 
higher magnitude (Kuniyasu, Takahashi et al. 2000, Baecher-Allan, Brown et al. 2001). IL-2 
signaling is needed for development of Tregs in the thymus as well as their expansion and 
maintenance in the periphery (Nelson 2004).  
1.3.5.2 IFN-γ 
IFN-γ is a pro-inflammatory cytokine, important in innate and adaptive immune response 
against viral and intracellular bacterial infections. In addition, it is involved in tumor control 
and enhancing tumor immune response (Ikeda, Old et al. 2002, Rosenzweig and Holland 2005). 
It contributes to differentiation of CD4+ T cells into Th1 effector cells. In addition of helper T 
cells, it affects natural killer (NK) cells and CD8+ T cells. It can be produced in large amounts 
by Th1 effector cells (Dong 2006, Harrington, Mangan et al. 2006).  
1.3.5.3 IL-6 
Different cells such as, macrophages, dendritic cells and B cells express IL-6. IL-6 is involved 
in differentiation of CD4 effector T cells, in addition to B cells and macrophages (Diehl, 
Anguita et al. 2000). In addition, IL-6 is the major cytokine, inducing the production of the 
acute phase reactant, C reactive protein (CRP) from liver innate cells as a response and a sign 
of systemic inflammation (Schmidt-Arras and Rose-John 2016). 
1.3.5.4 Tumor necrosis factor alpha (TNF-α) 
TNF-α is generally regarded as a pro-inflammatory cytokine produced by different cells, e.g. 
macrophages and T cells. Moreover, TNF-α deficient mice exhibit lack of splenic B cell 
follicles (Pasparakis, Alexopoulou et al. 1996). However, TNF-α has been proved to have dual 
functions, promoting Treg expansion and increasing suppressive Treg function in addition to 
the cytokine’s pro-inflammatory properties (Grinberg-Bleyer, Saadoun et al. 2010).  
1.3.5.5 IL-10 
IL-10 can be produced by different leukocytes but also by epithelial cells. IL-10 has a dual 
function both as a pro-inflammatory and an anti-inflammatory cytokine. Deficiency in IL-10 
or the IL-10 receptor has been suggested to cause infantile inflammatory bowel disease (IBD) 
(Kotlarz, Beier et al. 2012) whereas IL-10 treatment in mice increased anti-tumor immunity 
and tumor specific CD8+ T cell activation (Fujii, Shimizu et al. 2001, Emmerich, Mumm et al. 
2012), which illustrate the dual functionality of the cytokine.  
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 1.3.6 Regulatory B cells 
Bregs are B cells with immune suppressive function. They have mainly been identified as 
producers of IL-10 (Fillatreau, Sweenie et al. 2002, Mizoguchi, Mizoguchi et al. 2002, Mauri, 
Gray et al. 2003). In recent years IL-10 producing Bregs with multiple phenotypes have been 
described both in human and in mouse models. CD5+ CD1dhi B (B10) cells (Yoshizaki, 
Miyagaki et al. 2012), CD138+ plasma cells (Shen, Roch et al. 2014), CD19+ CD24hi CD38hi 
CD1dhi cells (Blair, Norena et al. 2010) and CD19+ CD24hi CD27+ cells (Iwata, Matsushita et 
al. 2011) are examples on such Bregs. Whether the differences are because of existence of a 
specific Breg lineages or due to immunological environment is not yet known (Rosser and 
Mauri 2015).  
It has been demonstrated in different studies that IL-10 producing Bregs also express other 
regulatory cytokines, such as TGF-β and IL-35. TGF-β produced by lipopolysaccharide (LPS)-
activated B cells can induce apoptosis in CD4+ effector cells (Tian, Zekzer et al. 2001) and 
chimeric mice with B cell specific IL-35 deficiency, developed more severe experimental 
autoimmune encephalomyelitis (EAE) and better protected against Salmonella-induced sepsis. 
In the Salmonella case, B cells with lack of IL-35, resulted in induction of Th1 cell responses 
and increased number of macrophages in the spleen (Shen, Roch et al. 2014).  
1.4 CANCER 
Despite modern therapeutic strategies, cancer continues to be one of the main causes of death 
worldwide. Further understanding of cellular and molecular events behind development of 
cancer, as well as the body’s immune alteration and response during the progression of the 
disease will help the ongoing human battle against cancer.  
1.4.1 Development 
There are several different capabilities that cells need to acquire in order to develop into cancer 
cells. As described by Hanahan et al. sustaining proliferative signaling is one of the main 
attributes. Normal tissues have controlled production and secretion of growth-promoting 
signals that regulate the cell proliferation and number and can therefore keep the tissues 
architecture and function intact. By ungoverned production of these growth signals, cancer 
cells lose control over their destiny (Hanahan and Weinberg 2011). In addition to sustaining 
growth signals, cancer cells must escape the body’s negative regulation of cell proliferation. 
Furthermore, they must resist cell death by apoptosis. p53 is a protein which can stop cells 
cycle progression in case of growth-promoting signals or glucose are produced in abnormal 
levels. In addition, it can cause apoptosis if irreparable damage in the genome has occurred. It 
has been demonstrated that mice lacking p53 develop leukemia and sarcoma (Ghebranious and 
Donehower 1998). Thus, p53 is as an example of the mentioned regulators of cell proliferation, 
which cancer cells must evade to develop. Another requirement, is unlimited replicative 
potential. There are verifications that telomeres protecting the end of chromosomes are 
involved in the capability for unlimited cell divisions (Shay and Wright 2000, Blasco 2005). 
Telomerase is a DNA polymerase that adds telomere to the end of telomeric DNA. Non-
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 immortalized cells almost lack telomerase whereas approximated 90% of spontaneously 
immortalized cells produce it at functional levels.  
In order to survive, tumors are in need of nutrients and oxygen, like normal tissues. Thus, 
induction of angiogenesis is another requirement for tumor growth, as well as activating 
invasion and metastasis. In some aggressive carcinomas cell-to-extracellular matrix and cell-
to-cell adhesion molecules are expressed in abnormal levels. Metastasis is believed to begin 
with local invasion followed by penetration of tumor cells into the blood or lymphatic vessels. 
Then the cells escape from the vessels into distant tissues where they become micro-metastases 
and thereupon grow to macroscopic tumors (Hanahan and Weinberg 2011). 
1.4.2 Cancer immune response 
Tumor infiltrating lymphocytes (TILs) are accepted as components of tumors. Many TILs, in 
particular T cells have been correlated with positive prognosis in patients with different 
malignancies such as melanoma, breast cancer, ovarian cancer, esophageal carcinoma, and 
urothelial carcinoma. (Clemente, Mihm et al. 1996, Schumacher, Haensch et al. 2001, Zhang, 
Conejo-Garcia et al. 2003, Pages, Galon et al. 2010). Cytotoxic T cells and NK cells can kill 
malignant cells directly and contribute to increased patient survival (Camus, Tosolini et al. 
2009, Marcus, Gowen et al. 2014), hence they are usually thought as the most important cells 
with anti-tumoral activity. However, other immune cells have emerged as strong contributors 
in tumor immune response, such as B cells. 
1.4.2.1 B cell immune response against cancer 
B cells can contribute in cancer immune responses in multiple ways. They can present tumor 
antigen to CD4+ T cells, using MHC class II. (Rodriguez-Pinto 2005, Yanaba, Bouaziz et al. 
2008). Notably the high-affinity binding of the Ig receptor to its specific antigen makes B cells 
unique compared to other APCs. Furthermore, they can produce tumor antigen specific 
antibodies (Reuschenbach, von Knebel Doeberitz et al. 2009). In addition, they can produce 
granzyme B (Hagn, Schwesinger et al. 2009) that upon secretion with perforin may trigger 
apoptosis in tumor cells. They can also produce cytokines and chemokines that regulate other 
immune cells. Notably, B cells promote the formation of CD4+ memory T cells (Whitmire, 
Asano et al. 2009) and facilitate survival of proliferation of activated CD8+ T cells through 
CD27-CD70 binding (Deola, Panelli et al. 2008).  
It has been demonstrated that B cells represent a significant portion of TILs and exhibit anti-
tumoral immune responses in colorectal cancer (Shimabukuro-Vornhagen, Schlosser et al. 
2014). Moreover, B cells are detected in approximately 25% of breast cancers and B cells may 
constitute up to 20% of the TIL population (Chin, Janseens et al. 1992, Marsigliante, Biscozzo 
et al. 1999, Coronella-Wood and Hersh 2003). Furthermore, TIL-Bs in collaboration with 
tumor infiltrating CD8+ T cells correlated with survival in ovarian cancer (Milne, Kobel et al. 
2009). As we demonstrated in our previous studies, B cell immune response against tumor 
antigen is not restricted to TIL-Bs and could be detected in tumor associated lymph nodes 
(Zirakzadeh, Marits et al. 2013). Investigations with a murine mouse model by others have 
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 confirmed our observations and identified tumor B cell immune response in tumor draining 
lymph nodes (TDLN). CD40 stimulation of TDLN isolated B cells and dendritic cells, in 
combination with CD3 stimulation of T cells, induced antitumor response. However, 
combination of either B cells or dendritic cells with T cells, exhibited a decreased antitumor 
response, which signifies the importance of the combination (Li, Teitz-Tennenbaum et al. 
2009). Thus, B cells are important participants of the anti-tumor immune response and they are 
beneficial for patient survival.  
In addition to B effector cells, tumor infiltrating Bregs have been encountered but on the 
contrary to the former, they appear to be disadvantageous to patient prognosis. They have been 
detected in tumors and metastasis with advanced colorectal cancer, in considerable numbers 
(Shimabukuro-Vornhagen, Schlosser et al. 2014).  
1.4.3 Cancer immune escape mechanisms 
Cancer immune escape starts after two other immune editing processes namely elimination and 
equilibrium. Elimination is the starting point of immunosurveillance. Tumor cells are 
recognized by the immune system and finally get eliminated. Equilibrium occurs when 
pressure of immune defense on tumor cells is enough to contain them but not enough to fully 
eradicate them. Tumor cells at that point are genetically unstable and rapidly mutating. During 
this process, the tumor cells acquire additional immune escape mechanisms, making them more 
resistant to the immune defense. This phase is likely the longest of the three processes and may 
continue during many years. Immune escape represents the final phase when the tumor cells 
acquire insensitivity to be recognized by the immune defense and/or to get eradicated. Thus, 
they begin to expand in an uncontrolled way. (Dunn, Bruce et al. 2002).  
There are many mechanisms by which tumor can evade immune recognition. One of them is 
by producing immune suppressive cytokines and/or by attracting regulatory immune cells, in 
addition to down regulating pro-inflammatory cytokines, such as IFN-γ. Among the cytokines, 
which have shown to exhibit immune suppression in the tumor, IL-10 and TGF-β can be 
mentioned. Increased levels of the cytokines, correlated with loss of CD3-ζ expression on TILs 
in pancreatic cancer patients. (von Bernstorff, Voss et al. 2001). CD3-ζ is part of the T cell 
receptor complex and lack of it, inhibits tumor specific antigen signaling, which in turn 
contributes to immune tolerance. One way for tumor cells to be recognized by the immune 
system is presenting tumor specific antigens to cytotoxic T cells, by human leukocyte antigen 
(HLA) class I. However, tumors can downregulate HLA class I as a frequent mechanism to 
evade the immune system. 96% of HLA class I loss have been reported in cervical and breast 
carcinomas (Cabrera, Angustias Fernandez et al. 1996, Koopman, Corver et al. 2000). Another 
mechanism, by which tumor escape can occur, is down-regulation of immunogenic tumor 
specific antigen by the tumor. In addition, tumors in many malignancies overexpress self-
proteins that makes it difficult for the immune system to recognize the tumor as foreign. In 
addition, APCs capture tumor antigen and present it to T cells. In the absence of pro-
inflammatory environment, caused by the tumor suppressive mechanism, APCs fail to mature, 
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 up-regulate costimulatory molecules and get activated; hence potent tumor antigen presentation 
fails which leads to immunological tolerance (Pinzon-Charry, Ho et al. 2005).  
The tumor may also upregulate proteins, leading to negative stimulatory effects, such as CTLA-
4. CTLA-4 has been demonstrated to be expressed by tumor cells and trigger apoptosis in target 
cells (Contardi, Palmisano et al. 2005). In addition, programmed death receptor 1 (PD1) and 
programmed death receptor ligand 1 (PDL-1) contribute to suppression of the immune system. 
It has been revealed that PDL-1 expression on tumor cells have a negative impact on the 
malignant cells and have a negative prognosis for cancer patients (Blank and Mackensen 2007).  
1.4.4 Cancer treatments 
1.4.4.1 Chemotherapeutic drugs 
Chemotherapy is one of the primary treatments for cancer patients. Doxorubicin (Adriamycin), 
cisplatin and irinotecan are among the conventional chemotherapeutic drugs used for 
chemotherapy today. According to national cancer institute (NCI) as part of national institutes 
of health (NIH), Doxorubicin is used for treatment of malignancies such as, acute 
lymphoblastic leukemia (ALL), breast cancer, gastric cancer, ovarian cancer, small cell lung 
cancer, thyroid cancer, urinary bladder cancer, etc. It is one of the most potent 
chemotherapeutic drugs approved (Carvalho, Santos et al. 2009). Its ability to engage rapidly 
dividing cells and to induce slow disease progression has been widely known and 
acknowledged for decades. It is limited only by its toxicity on normal cells in the body (Tacar, 
Sriamornsak et al. 2013).  
The role of Topoisomerase II is to cut and religate DNA strands in order to unknot DNA tangles 
and supercoils and make the strands ready for replication. Doxorubicin at low concentrations 
(<1μM), functions by blocking DNA religation during the activity of topoisomerase II, hence 
preventing DNA replication. At high concentrations (>10μM), doxorubicin intercalates 
between base pairs in the DNA helix, preventing topoisomerase II from binding to the DNA, 
thereby prohibiting DNA replication (Pommier, Leo et al. 2010). In highly proliferating cells, 
such as cancer cells, topoisomerase II activity is high which makes doxorubicin an effective 
drug to combat cancer.  
Cisplatin is used to treat severe forms of bladder cancer, ovarian cancer, testicular cancer, etc. 
In addition to doxorubicin, it is one of the most potent chemotherapeutic drugs used to treat 
cancer patients. There are two chloride ligands included in the molecule, one of which is 
spontaneously displaced with a water molecule in the body. This so called aquation process 
leads in turn, to the water molecule to be replaced with a DNA base, and hence the molecule 
binds to the DNA. The other chloride ligand can in turn be replaced with another DNA based 
leading to crosslinking the DNA. Different repair mechanisms arise for the damaged DNA but 
when repair proves impossible, cell apoptosis will be induced (Siddik 2003).  
Irinotecan is mainly used for treating colorectal cancer with metastasis. It is a prodrug which 
is hydrolyzed to its active form, SN-38, in the body. It functions by binding the interface of the 
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 cleaved DNA during topoisomerase I activity (Pommier 2013). Thus, the enzyme gets 
inactivated, leading to prevention of DNA replication and transcription.  
MVAC is a chemotherapeutic regimen based on cisplatin, which in addition to the mentioned 
drugs, involves three other immunotherapeutic agents, methotrexate, vinblastine and 
doxorubicin (Adriamycin) (Meeks, Bellmunt et al. 2012). It is widely used in neoadjuvant 
chemotherapy for advanced bladder cancer patients (Witjes, Comperat et al. 2014) when the 
regimen is administered before cystectomy.  
Despite the side effects the chemotherapeutic drugs can exhibit on normal cells, including the 
cells of the immune system, there have been reports about increased immune antigen response 
as an effect of cell treatment with chemotherapeutic drugs and induction of activation 
phenotypes upon drug treatment (Moschella, Valentini et al. 2011, Hu, Kinn et al. 2013). In 
addition, it has been demonstrated that chemotherapy in combination with presence of TILs 
contributes to an improved prognosis in breast cancer (Denkert, Loibl et al. 2010). One 
explanation for the synergistic effect of the drugs and the immune system is that in addition to 
DNA, cellular molecules and proteins may act as potential targets which could have an 
activating effect on the immune cells (Hato, Khong et al. 2014). Further studies are needed to 
dissect the mechanism of chemotherapeutic agents on the immune cells.  
It has been illustrated that immunotherapy may have synergistic effects with chemotherapy 
(Godet, Fabre et al. 2012). However, optimizing the administration plans might be crucial to 
achieve a successful response as administration of the drugs in a vulnerable phase of the 
leucocyte activation and proliferation may have an adverse effect.  
1.4.4.2 Immunotherapy 
Immunotherapy has increasingly become attractive to treat cancer patients. IFN-α2 and IL-2 
have been used to treat melanoma (Kirkwood and Ernstoff 1985, Kirkwood, Butterfield et al. 
2012). Another way to stimulate the immune system against cancers is to use identified tumor 
antigens as vaccines. Tumor antigens stimulate a cellular and/or a humoral immune response 
in cancer patients (Sahin, Tureci et al. 1995). They can promote epitopes that are presented by 
the tumor cells using MHC class I to activate CD8+ T cells. In addition they can give rise to 
fragments presented to CD4+ T cells by APCs, using MHC class II. Dendritic cells (DCs) have 
an important role in immunotherapy. A way to make sure that tumor antigen is delivered and 
proper signal for immunization is induced, is loading patient DCs with tumor antigen ex vivo 
before transfusion in their host (Schuler, Schuler-Thurner et al. 2003). In addition, we have 
previously demonstrated that CD4+ T cell adoptive immunotherapy is a promising treatment 
for muscle-invasive bladder cancer and colon cancer patients (Karlsson, Marits et al. 2010, 
Sherif, Hasan et al. 2015). Ex vivo expansion of Tumor infiltrating CD8+ T cells, using IL-2, 
is another method used by others to treat melanoma (Rosenberg, Yang et al. 2011). Hybridoma 
technology has facilitated production of highly specific antibodies against tumor antigens. 
Monoclonal antibodies, such as rituximab (anti-CD20) and trastuzumab (anti-human epidermal 
growth factor 2 [HER-2]) are routinely used for treatments against lymphoma and breast cancer 
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 respectively (Campoli, Ferris et al. 2010). Another treatment being tested on patients with high 
scale, is adoptive T cell therapy with chimeric antigen receptors (CARs). The idea is that T 
cells are removed from the patients and genetically engineered to produce single chain 
fragment variable (scFv) of a monoclonal antibody, targeted against tumor associated antigens. 
From the inside the cells, scFvs are connected to the signal transduction machinery of the T 
cells. The therapy has shown promising results although some toxicity has been encountered, 
especially when the expression of targeted tumor antigen is shared with healthy tissues 
(Casucci and Bondanza 2011). Further studies are needed to optimize immunotherapy and 
increase a tumor specific immune response by multiple immune mediators working in 
combination to combat cancer.  
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 2 AIMS OF THE THESIS 
The overall aim of this thesis was to study B cells in patients with solid malignancies and to 
investigate their immune response against tumors, in order to address their antigen presenting 
ability. Tumor specific B cells as potent APCs may be beneficial to utilize in CD4+ T cell 
adoptive immunotherapy.  
The specific aims for each study were: 
Paper I. To characterize subpopulations of B cells in blood, metastatic lymph nodes and tumor 
of patients with malignancies and to examine their phenotypes.  
Paper II. To investigate the effect of chemotherapeutic drugs on human B cells with respect 
to their antigen presenting ability.  
Paper III. To study the impact of tumor associated B cells, CD38+ cells and IL-10 on survival 
of patients with urinary bladder cancer.  
Paper IV. To examine the existence of Ig κ+ Ig λ+ B cells in cancer patients and reveal their 
phenotype and properties.  
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 3 MATERIALS AND METHODS 
This chapter contains a summary of the patients and methods used in the studies included in 
the thesis. For more detailed information please refer to the respective study.  
3.1 PATIENTS 
3.1.1 Patient characteristics 
Over all 20 patients were included in paper I and in group 1 in paper IV. 5 colon cancer (CC), 
9 Urinary bladder cancer (UBC), 4 malignant melanoma (MM), 1 pancreatic cancer (PC) and 
1 patient with prostate cancer (PrC), between ages 47-86. 16 of the patients were male whereas 
4 were females.  
In paper II, 15 patients with muscle invasive urinary bladder cancer (MIBC), between the ages 
55-86, were included. They were 11 males and 4 females with clinical tumor stages between 
T2-T4. In group 2 from paper IV, 19 UBC patients, 14 males and 5 females were included. The 
patients underwent TUR-B operation after which 8 patients received neoadjuvant 
chemotherapy (NAC) containing the chemotherapeutic drug, Doxorubicin. Depending on post 
NAC clinical data and response of the patients, they underwent cystectomy. 
In paper III, 33 muscle invasive UBC patients were included in the retrospective study, where 
paraffin embedded tumor sections from 24 males and 9 females between the ages of 46-81 
were studied. The patient had been cystectomized at the Karolinska University hospital during 
1999-2002. Last updated patient survival data was received on 18th of October 2015.  
3.1.2 Specimens 
Metastatic and non-metastatic lymph nodes (papers I and IV), in addition to blood, primary 
tumor and in some cases macroscopically non-malignant urinary bladder tissue (paper I) were 
collected for the prospective studies. Furthermore, blood (papers II and IV) and tumor (paper 
IV) were collected at the time of TUR-B operations. Blood (papers II and IV), sentinel and 
non-sentinel nodes (paper IV) were collected at cystectomies. In addition, blood samples from 
healthy donors were obtained for papers I and IV.  
4 μm paraffin embedded tumor sections on glass slides were obtained for a retrospective study 
in paper III.  
3.1.3 Identification of metastatic and sentinel lymph nodes 
Metastatic lymph nodes were detected by either pathological examination or by using flow 
cytometry as described in our previous studies (Karlsson, Nilsson et al. 2008, Hartana, Kinn et 
al. 2016). Sentinel nodes were identified by radioactive isotope injection around the tumor and 
measuring the radioactive signal by a handheld Geiger meter (Sherif, De La Torre et al. 2001, 
Rosenblatt, Johansson et al. 2016).  
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3.1.4 Cell preparation 
Cells from the specimens in paper I, II and IV, were obtained within 2 hours after each 
operation. PBMC were isolated from blood using density centrifugation (Ficoll-Paque plus; 
GE Healthcare). Single-cell suspensions from the lymph nodes were collected by firstly cutting 
the specimens into smaller pieces. Then by either using a glass homogenizer (paper I and group 
1 in paper IV) or by gentle pressure on 100 μ cell strainers (group 2 in paper IV), single cell 
suspensions were isolated. Primary tumors and non-malignant tissues were homogenized, 
using GentleMACS dissociator (Miltenyi biotec) in 10 ml RPMI 1640 (Sigma) for paper I and 
group 1 in paper IV, or 10 ml AIM V (GIBCO; Life Technologies) for paper II and group 2 in 
paper IV, containing 1% collagenase/Hyaluronidase solution (Stem cell technologies).  
3.2 IMMUNOLOGICAL ANALYSIS 
3.2.1 Flow cytometry 
3.2.1.1 Surface staining 
Single cell suspensions were freshly used for flow cytometry. In paper I and group 1 in paper 
IV, the cells were washed and stained in FACS buffer, containing PBS, 2.5% bovine growth 
serum and 0.05% NaN3. In paper II and group 2 in paper IV, the cells were firstly washed with 
PBS before they were stained with blue LIVE/DEAD Fixable blue dead cell stain kit (Life 
technologies) according to the manufacturer’s protocol. The cells were then washed with PBS 
again and stained with surface antibodies in PBS. Flow cytometry was carried out with either 
FACS Aria (BD biosciences) or with FACS Fortessa (BD biosciences). The data were analyzed 
using FACSDiva software (BD biosciences).  
3.2.1.2 Flow cytometry and assay of specific cell mediated immune response 
To analyze T cell lymphoblasts in paper II, the cells were stained with surface antibodies 
according to the above mentioned procedure. FACS Aria was used to acquire the cells. Smaller 
non-granular lymphocytes and larger lymphoblasts were identified based on their position on 
dot-plots showing forwards-scatter and side-scatter. T cell lymphoblasts (CD3+, CD4+, HLA-
DR+, CD45RO+) were gated and analyzed using a flow cytometric assay of specific cell 
mediated immune response (FASCIA) (Svahn, Linde et al. 2003). The ratio of the T cell 
lymphoblasts were calculated according to the following formula: 𝑛𝑛 = 𝑇𝑇 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑐𝑐𝑙𝑙𝑙𝑙𝑙𝑙ℎ𝑜𝑜𝑜𝑜𝑐𝑐𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜
Total T cells  
3.2.1.3 Intracellular staining 
Doxorubicin treated and untreated B cells, sorted from 5 healthy blood donors were treated 
with PMA, Ionomycin and Golgiplug. The cells were then fixed and permeabilized using 
Cytofix/Cytoperm solution kit (BD biosciences) according to the manufacturer’s protocol. 
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 Anti-human IL-10 antibody (allophycocyanin; JES3-19F1; Biolegend) was used to stain the 
cells. Rat IgG2a, κ antibody (allophycocyanin; RTK2758; Biolegend) was used as isotype 
control, before cytometry analysis was carried out (paper II).  
3.2.2 Spectratype analysis  
In paper I, DNA was extracted from PBMC, lymph nodes, tumor and nonmalignant tissue from 
a 61 year old female UBC patient, using DNA lysis buffer pH 8.0 (10 mM Tris, 1 mM EDTA, 
1% SDS) and proteinase K. The DNA samples were incubated in 56o C for 10 minutes before 
they were purified using phenol:chloroform:isoamyl alcohol 25:24:1, saturated with 10 mM 
Tris, pH 8.0, 1 mM EDTA (Sigma-Aldrich). Following centrifugation, the upper phases were 
separated from the rest of the samples before 3 M sodium acetate (NaOAC) and 100% ethanol 
were added. Stepwise rehydration followed resuspension in ultrapure water.  
PCR was then performed based on 7 B cell Vh subgroups using 7 forward primers against 
frame 3 region in each subgroup and a universal 6-FAM-conjugated reverse primer against Jh 
region. GOTaq master mix (Promega) was used to perform the PCR according to the 
manufacturer’s protocol. 
Spectratype analysis was then carried out using Gene Scan 400 HD size standard, Hi-Di 
formadide and ABI 3730 DNA Analyzer (Applied Biosystems). The software Peak Scanner 
(Applied Biosystems) was used to analyze the data.  
3.2.3 Sequencing 
PCR products for the above mentioned spectratype analysis, were purified with QIAquick PCR 
purification kit (Qiagen) before they were cloned using TOPO TA Cloning Kit for Sequencing 
with TOP10 chemically competent cells (Invitrogen). The plasmids were then purified with 
Plasmid Mini Kit (Qiagen) and then sequenced for paper I, using ABI 3730 DNA analyzer 
(Applied Biosystems).  
3.2.4 Cell sorting 
In Paper II, PBMCs were isolated from blood of healthy donors as described above. Magnetic 
beads were then used to isolate B cells and CD4+ T cells from the PBMCs with CD19+ B cell 
isolation kit (positive selection) and CD4+ T cell isolation kit II (negative selection) (Miltenyi 
Biotec, Bergisch Gladbach, Germany) respectively, and an autoMACS separator (Miltenyi 
Biotec, Bergisch Gladbach, Germany). For figure 2 in paper II, B cells were isolated from the 
PBMCs with CD19+ B cell isolation kit (positive selection) (Stem cell). All the sorting 
experiments were carried out using manufacturer’s protocol.  
3.2.5 In vitro cell culture media and reagents 
In Figure 1, paper II, Roswell Park Memorial Institute (RPMI)-1640 cell culture medium 
(Sigma-Aldrich, St Louis, MO, USA) in addition to 1% L-glutamin, 1% 
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 penicillin/streptomycin and 10% FCS (Hyclone, Logan, UT, USA), whereas in figure 2 and 
4D, AIM V medium (GIBCO; Life Technologies) were used.  
The cells in paper II were treated with one of the three conventional chemotherapeutic drugs, 
Irinotecan, Cisplatin or Doxorubicin in the concentrations 125 μM, 25 μM or 0.2 μM 
respectively. The concentrations of the drugs were obtained by a titration in our previous study 
where LD50 of the treated cells were achieved.  
3.2.6 In vitro cell culture 
Following the isolation of CD19+ cells and CD4+ T cells in paper II (figure 1), B cells were 
treated with one of the three mentioned chemotherapeutic drugs in RPMI medium. CD4+ T 
cells were incubated in RPMI medium alone. To prepare the negative control, the isolated B 
cells were cultured in RPMI alone whereas CD4+ T cells were treated with the three 
chemotherapeutic drugs. All cells were incubated in +37o C, overnight. The next day, the B 
cells and the T cells were washed twice and cultured together at a 1:2 ratio respectively. In 
addition, Staphylococcal enterotoxin B (SEB) was added (5 μg/ml) and the cultures were 
incubated in +37o C for the indicated number of days before they were harvested for FASCIA 
analysis.  
In figure 2, paper II, isolated CD19+ cells were cultured in AIM V medium and with or without 
doxorubicin, at a concentration of 1x106 cells/ml. The cells were then incubated at 37o C for 
12 hours.  
In paper 4, the muscle invasive cell line, 5637 (ATCC), was cultured in AIM V medium. The 
supernatant after 70% cell confluence was gathered and stored in -70o C. PBMCs from a 
healthy donor were then cultured in the 5637 supernatant in the concentration gradients, 0%, 
25%, 50%, 75% and 100%, in addition to AIM V medium, in +37o C. The cells were then 
collected for flow cytometry analyses at day 2, 3 and 4.  
3.2.7 CD86 blocking experiment (paper II) 
Sorted healthy human B cells from peripheral blood were cultured with or without Doxorubicin 
in cell culture medium and incubated in +37o overnight. The following day, the cells were 
washed and incubated with anti-CD86 blocking antibody (1 μg/ml) for 30 minutes before they 
were washed again. The cells were then cultured with untreated CD4+ T cells. Finally SEB (5 
μg/ml) was added to the cultures.  
3.2.8 Cytokine analyses  
Supernatants from day 2 culture of the CD86 blocking experiment mentioned above, were 
collected and stored in -20o C. Before the cytokine experiment, the supernatants were thawed 
and sent to Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, 
for Luminex 14-plex cytokine analysis.  
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 3.2.9 Reverse transcription-quantitative PCR (paper IV) 
Ig κ+, Igλ+ single positive and double positive Ig κ+ Igλ+ B cells from a sentinel node of a UBC 
patients were sorted using FACS Aria. Messenger RNA (mRNA) was then extracted from each 
population and quantified by NanoDrop 1000 before cDNA synthesis was carried out using 
iScript Reverse Transcription Supermix for RT-qPCR (Bio-Rad). QT PCR was performed with 
primers for the activation-induced cytidine deaminase (AID) gene, fwd: 5’-
CACCACTATGGACAGCCTCTTG-3’, rev: 5’-ACTGTCACGCCTCTTCACTAC-3’ and 2x 
SYBR Select Master Mix (Life Technologies), using CFX96 Real-Time System (BioRad). The 
data were analyzed with CFX Manager Software (Bio-Rad). The expression level of AID 
transcript was calculated with respect to RNA polymerase II (RPII) as a housekeeping gene. 
The expression levels were normalized to Ig κ as control.  
3.2.10 Immunohistochemistry 
In paper III, paraffin embedded tumor sections were incubated in 60o C for 1 hour and 
deparaffinized in xylene following rehydration in ethanol dilution series, 100%, 95% and 70%. 
Heat-based antigen retrieval was carried out using Tris-EDTA buffer (pH 9.0). The primary 
antibodies used in this paper were monoclonal mouse anti-human CD20 (Abcam, Cambridge, 
UK, 1:20 dilution), rabbit polyclonal anti-human IL-10 (Abcam, 1:400 dilution) and 
monoclonal rabbit anti-human CD38 (clone EPR4106; Abcam, Cambridge, UK, 1:100 
dilution). To stain the secondary antibody, the VECTASTAIN Elite ABC kit was used 
according to the manufacturer’s protocol and visualization was performed using 
diaminobenzidine (DAB) kit (SK-4100, Vector Laboratories). The sections were then counter 
stained with Mayer’s haematoxylin (1 minute).  
Following deparaffinization, rehydration and antigen retrieval as mentioned above, 
endogenous peroxidase and alkaline phosphatase activity were blocked with BLOXALL 
Blocking solution (Vector Laboratories) for double staining of the sections. Unspecific protein 
binding was blocked with 2.5% normal horse serum following incubation with the first primary 
antibody CD20 (Abcam, Cambridge, UK). The first secondary antibody, ImPRESS Alkaline 
Phosphatase Reagent kit (Vector Laboratories) was stained according to the manufacturer’s 
protocol. Visualization was performed using VECTOR Blue Alkaline Phosphatase substrate 
kit (Vector Laboratories). Blocking unspecific protein binding as mentioned above, was then 
followed by second primary and secondary antibodies, rat anti-human CD3 (Bio-Rad) and 
ImPRESS HRP Reagent kit (Peroxidase): Goat anti-Rat IgG, mouse adsorbed (Vector 
laboratories), respectively. ImPACT NovaRED Peroxidase substrate kit (Vector laboratories) 
was used to visualize the second staining. For negative control, the primary antibodies were 
not added.  
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 3.3 EVALUATION AND STATISTICAL ANALYSIS 
In paper I, the comparisons were made using Student two-tailed unpaired t-test and Mann–
Whitney U test using the GraphPad Prism software. The Ig λ/Ig κ L chains proportions were 
analyzed using Fisher’s F-test.  
In paper II, the data were compared using paired t-test and Mann-Whitney U test. P-values < 
0.05 were considered significant. 
When evaluating CD20 and IL-10 stained sections in paper III, 3 random field with 4x 
magnifications were selected and photographed in consecutive slides from each patient. The 
photographs were then evaluated by 2 independent observers. When evaluating CD38 stained 
sections, 5 fields with highest numbers of positive cells were photographed. The positive cells 
were then counted by 2 independent observers. Finally Kaplan Meier curves were plotted with 
survival data and the data were analyzed using Log-rank (Mantel-Cox) test. Data from patients 
with non-cancer specific death before 5 years of survival were excluded. The data in figure 3, 
paper III were analyzed using Mann-Whitney U test in Graphpad prism software.  
In paper IV, the data were analyzed using unpaired t-test and Mann-Whitney U test in 
GraphPad Prism software. 
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 4 RESULTS AND DISCUSSION 
4.1 MULTIPLEX B CELL CHARACTERIZATION IN BLOOD, LYMPH NODES 
AND TUMOR FROM PATIENTS WITH MALIGNANCIES  
B cells can contribute to the immune defense against cancer in multiple ways. In particular 
their high affinity binding Ig receptor can bind to low amount of antigens in the surroundings 
which makes them unique compared to other professional APCs. Thus, the role of B cells as 
APCs may prove to be important in cellular cancer immunotherapy. Before this study was 
conducted, B cells were comparatively scarcely investigated in cancer patients, which 
constituted one of the triggering factors to begin the study. An ideal beginning was to examine 
subpopulations of B cells in blood, lymph nodes and tumor from patients with solid tumor, 
using the Freiburg B cell classification (Wehr, Kivioja et al. 2008).  
We found no difference between the proportion of blood-borne CD19+ cells in patients and 
healthy donors. However, in metastatic lymph nodes (MLNs), we found increased transitional 
B cells compared to non-metastatic lymph nodes (NMLNs), which suggests recruitment of the 
B cell subpopulation to the MLNs. In addition, plasmablasts and CD86+ expressing proportions 
of CD19+ B cells, were increased in MLNs compared to NMLNs, which demonstrates B cell 
activation. This hypothesis strengthened when we studied B cell subpopulations in the tumor 
and compared them with their counterparts in non-malignant tissues. We observed increased 
proportions of switched memory B cells and plasmablasts among tumor infiltrating 
lymphocytes (TIL-Bs). In addition, TIL-Bs exhibited distinct skewing of Igλ/Igκ ratios among 
TIL-Bs demonstrating clonal B cell expansion. To investigate further, we performed a 
spectratype analysis of the complementarity determining region 3 (CDR3) of the B cell heavy 
chain receptor, IgH, in a UBC patient (Figure 3). We demonstrated a monoclonal expansion of 
the Vh7 family in the tumor, thus strengthening our previous Igλ/Igκ ratio observation. The 
CDR3 length of the expanded IgH in the tumor could also be observed as the highest peak in a 
tumor-associated lymph node, demonstrating that the same clonal expansion was seen in a 
tumor draining lymph node. To further analyze the single clonal expansion in the tumor, we 
cloned the CDR3 region and sequenced 3 clones. In frame 3 (FR3), we observed a WRCY 
hotspot motif where a serine in the corresponding germline region had been changed to glycine. 
Furthermore, one of the clones displayed a mutation in the CDR3 region, switching glycine 
into glutamic acid, which suggests ongoing somatic hyper mutation in the tumor.  
Thus, our investigation revealed B cell activation in tumor-associated-tissues, which suggest 
tumor antigen encounter by the B cells. Increased proportions of switched memory B cells and 
plasmablasts suggest CD4+ T cell dependent responses strongly supported by the observation 
of somatic hyper mutation and clonal expansion in the tumor.  
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 4.2 DOXORUBICIN ENHANCES THE CAPACITY OF B CELLS TO ACTIVATE T 
CELLS IN UROTHELIAL URINARY BLADDER CANCER 
Chemotherapy is currently the conventional treatments for cancer patients. However, 
chemotherapy gives rise to multiple side effects, including suppression of the immune system. 
On the contrary to this belief, we demonstrated in a previous study that chemotherapeutic drugs 
could enhance the immune system (Hu, Kinn et al. 2013). In addition, a combination of 
chemotherapy and immunotherapy has shown to be beneficial for patients with non-small cell 
lung cancer (Zhong, Teng et al. 2011). 
In this study, we set out to investigate the effect of three conventional chemotherapeutic drugs, 
doxorubicin, cisplatin and irinotecan on human B cells. We demonstrated that B cells treated 
with doxorubicin, exhibited increased expression of the costimulatory molecule CD86 and 
subsequently leading to increased CD4+ T cell activation in presence of the super antigen, 
staphylococcus aureus enterotoxin B (SEB). In addition, this effect could be inhibited by using 
a CD86 blocking antibody. We suggest that doxorubicin can induce CD86 expression that in 
turn, contributes to increased T cell activation.  
 
VH (46-52) DH (27) JH (6) C
VH DH JHVH (46-52) D  (27) JH (6)
CDR1 CDR2 CDR3
CDR1 CDR2 CDR3 DH JH
Forward primer
Reverse primer
A
B
C
Figure 3. The schematic overview of heavy chain variable region. (A) The variable 
region in the genome consists of 46-52 V segments, 27 D segments and 6 J segments. 
(B) During receptor gene rearrangements, a V, a D and a J segment fuse together 
randomly to constitute a variable region, ready to be transcribed. Highly variable 
CDR1, CDR2 and CDR3 are included in the V segment, which comprise B cell heavy 
chain specificity. (C) The position of the primers used in paper I for polymerase chain 
reaction (PCR) and the following spectratype analysis.  
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 Furthermore, we demonstrated that treating B cells with doxorubicin could inhibit secretion of 
anti-inflammatory cytokines, IL-10 and TNF-α (p = 0.040 and p = 0.026 respectively) in the 
co culture of B cells and T cells. When we compared IL-6/IL-2 secretion ratios, we found out 
increased relative contribution of IL-6 when B cells were treated with doxorubicin (two folds) 
further suggesting pro-inflammatory effect of doxorubicin.  
To address the effect of doxorubicin on regulatory B cells (Bregs), isolated CD19+ B cells were 
treated with doxorubicin and studied with respect to intracellular IL-10 expression. We 
demonstrated that doxorubicin contributed to decreased IL-10 expression. We suggest that 
doxorubicin inhibits Bregs and contributes to decreased total secretion of IL-10 in the B cell T 
cell culture.  
When investigating circulating B cells from UBC patients, we observed increased CD86-
expression in patients treated with neoadjuvant doxorubicin containing chemotherapy 
strengthening our in vitro findings.  
We conclude that chemotherapeutic drugs, especially doxorubicin, may contribute to enhance 
the immune system by increasing the antigen presenting ability of B cells. Further studies are 
needed to dissect the effect of doxorubicin and other chemotherapeutic drugs on the immune 
system. 
4.3 TUMOR-ASSOCIATED B CELLS IN URINARY BLADDER CANCER 
Tumor infiltrating lymphocytes (TILs) have been correlated with survival in cancer patients. B 
cells and plasma cells are important elements of these infiltrates. Tumor infiltrating B cells 
(TIL-Bs) have notably correlated with survival in different malignancies (Milne, Kobel et al. 
2009). However, their role in UBC patients remains obscure. In addition, we studied the 
expression of IL-10, a cytokine with both immunostimulatory and anti-inflammatory attributes.  
In this study, we used paraffin embedded tumor sections from 33 UBC patients to investigate 
the existence of B cells, CD38+ cells and IL-10 producing cells, in and around the tumor. Their 
correlation to patient survival was the next step in our investigation.  
CD20 staining of the sections, revealed follicle-like structures (FLSs) where the B cells had 
been accumulated in the proximity of the tumor. In addition, tendency towards increased 
patient survival with mean number of ≥ 1 FLS was demonstrated, suggesting the importance 
of B cell accumulation in the tumor. Double staining with CD20+ and CD3+ antibodies, 
unfolded CD3+ cell accumulation in the center of FLSs, with B cells coexisting both in the 
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 center and around the FLSs (Figure 4). This suggests B cell and T cell interaction in the 
proximity of the tumor of UBC patients.  
Furthermore, we demonstrated that in 38% of the patients, IL-10 was expressed, whereas in 
62%, no IL-10 expression was detected. Kaplan-Meier analysis illustrated a tendency towards 
increased survival for patients with IL-10 expression in their tumors. Median survival time of 
patients with no IL-10 expression was 3.0 years, whereas median survival time for IL-10 
positive group was 7.39 years. Thus, in addition to FLSs, IL-10 may be important for patient 
survival. When we examined both IL-10+ and IL-10- groups, increased mean numbers of FLSs 
in IL-10+ sections were exposed, which supports the above mentioned survival data for both 
phenotypes.  
We compared CD20 stained sections with consecutive IL-10 stained sections and discovered 
that IL-10 expression co-localized with B cells in 13% (n=3) of the patients. This suggests 
existents of Bregs in these tumor sections. Survival time of the patients with tumor-associated 
Bregs revealed to be poor compared to patients with lack of IL-10 expression (n=15) or patients 
with detached IL-10 expression (n=5).  
Finally, we demonstrated tumor-associated CD38+ cells in the tumor sections. The patients 
were divided into two groups; a high CD38+ cell group (mean number ≥200) and a low CD38+ 
group (mean number <200). We demonstrated a tendency towards increased survival for the 
high CD38+ cell group. CD38 is prominently expressed on plasmablasts and plasma cells. We 
suggest CD38 expression has a favorable effect in survival for UBC patients.  
We conclude, B cells and plasma cells in and around tumor, may contribute to survival in UBC 
patients. In addition, expression of IL-10 by tumor-associated Bregs may affect the survival 
negatively whereas IL-10 expression by other cells in the tumor may have a positive prognosis. 
More detailed studies are needed to dissect the role of B effector cells as well as regulatory B 
cells in cancer patients and to utilize the knowledge for designing more effective cellular 
immunotherapies.  
 
Figure 4. Representative example 
of a follicle-like structure. The 
structure comprise of B cells 
(blue) and CD3+ cells (red/brown) 
which accumulate in the proximity 
of the tumor.  
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 4.4 RARE B CELL POPULATION WITH DUAL EXPRESSION OF IG Κ AND Λ 
LIGHT CHAINS IN CANCER PATIENTS 
Since B cells rearrange their Ig receptors, it is generally accepted that they go through allelic 
exclusion, where they express a single unique heavy chain and a single unique light chain. 
However, in violation of allelic exclusion, B cells with dual Ig κ+ Ig λ+ light chain receptors 
have been encountered in anti-DNA transgenic mice and in human malignant B cells, e.g. in 
chronic lymphatic leukemia (CLL) (del Senno, Gandini et al. 1987, Li, Li et al. 2002).  
Comparatively, little is known about healthy human dual light chain positive B cells and even 
less about Ig κ+ Ig λ+ B cells in patients with solid tumors. In this study, we reported the 
prevalence of dual light 
chain positive B cells 
(Figure 5) and characterize 
their phenotypes in patients 
with solid malignancies.  
We demonstrated increased 
Ig κ+ Ig λ+ B cell proportion 
of CD19+ cells in MLNs 
compared to proportion of B 
cells with dual light chains in 
NMLNs. In addition, 
increased Ig κ+ Ig λ+ B cell 
proportion in sentinel nodes (SNs) compared to their counterparts in non-sentinel nodes (NSN) 
was observed which suggests emergence of Ig κ+ Ig λ+ B cells is due to the tumor environment. 
This hypothesis was strengthened by our observation of TIL-Bs where increased proportions 
of B cells with dual light chains compared to Ig κ+ Ig λ+ B cells in non-sentinel nodes, were 
detected (p<0.001).  
Ig κ+ Ig λ+ B cell population was present in both switched memory and activated B cell 
populations and they exhibited increased proportion of respective B cell subpopulations, in 
tumor associated lymph nodes compared to non-metastatic and non-sentinel lymph nodes 
respectively. This further supports our previous data about emergence of dual light chain B 
cells being due to the tumor environment.  
Furthermore, we detected no expression level of RAG2 in Ig κ+ Ig λ+ B cell RNA from a SN 
of a UBC patient, but demonstrated decreased expression of AID transcript in B cells with dual 
light chain receptor, compared to single light chain B cells from the same SN. Lack of RAG2 
and low levels of AID expressions, confirms inability of Ig κ+ Ig λ+ B cells to undergo somatic 
hypermutation, receptor rearrangements.  
To investigate whether tumor environment is a contributing factor behind the increased 
prevalence of Ig κ+ Ig λ+ B cells, we cultured PBMCs from a healthy donor with supernatant 
from the UBC cell line, 5637 (70% confluence). We demonstrated that the proportion of Ig κ+ 
 
Figure 5. Representative 
example of Ig κ+ Ig λ+ B cells 
in a lymph node from a 
patient with malignant 
melanoma. Flow cytometry 
analysis demonstrates CD19+ 
cells in the dot plot. The gate 
is set to illustrated Ig κ+, Ig 
λ+ and Ig κ+ Ig λ+ B cells.  
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 Ig λ+ B cells increased with increased concentration of the supernatant, during 4 days of culture. 
Thus, we revealed tumor environment to be an important contributing element in increasing 
the Ig κ+ Ig λ+ B cell population.  
We conclude the emergence of Ig κ+ Ig λ+ B cells in tumor associated specimen, is likely due 
to tumor environment. Many questions about the function of the B cells with dual light chain 
expression in cancer patients still remain to be answered. For example, whether they are 
effector cells or Bregs. More studies are needed to understand the role of Ig κ+ Ig λ+ B cells in 
cancer patients.   
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 5 CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES 
Previously we have demonstrated that activation and expansion of sentinel node derived, tumor 
reactive CD4+ T cells are promising for adoptive immunotherapy in cancer patients (Karlsson, 
Marits et al. 2010). For activation and subsequently expansion, T helper cells require 
encountering antigen in major histocompatibility complex (MHC) class II pocket of antigen 
presenting cells (APCs). Activation and expansion of APCs may therefore prove to streamline 
our immunotherapy setup further. There are three major APCs in lymph nodes, macrophages, 
dendritic cells and B cells (Itano and Jenkins 2003). B cells are the most abundant of the three 
APCs in the lymph nodes. In addition, their highly specific antigen binding receptor makes 
them unique in comparison to the other two APCs. Thus, tumor specific B cells may be 
effective APCs in the context of our CD4+ T cell based immunotherapy.  
In our studies, we have demonstrated increased plasmablast and switched memory B cell 
populations, in addition to signs of somatic hypermutation and clonal expansion in tumor 
associated tissues suggesting a tumor antigen presenting ability of B cells. Furthermore, we 
confirmed the existence of B cells and plasma cells in tumor sections and demonstrated B cell-
T cell interaction in follicle like structures (FLSs) in the proximity of the tumor. Moreover, we 
observed that increased FLSs and plasma cells in and round the tumor contributed to positive 
patient prognoses whereas Bregs seemed to be disadvantageous in patient survival. In addition 
to our studies, others have demonstrated B cell immune response against solid tumors 
(Shimabukuro-Vornhagen, Schlosser et al. 2014). However, B cells need further studies to 
dissect their APC abilities. The existence of regulatory B cells (Bregs) among sentinel node 
derived tumor specific B cells and the depletion of them from the culture intended for T cell 
expansion, need to be addressed. 
The next step is to set up an effective combination of cytokines and growth factors to expand 
the tumor specific B cells and keep them alive in culture during a longer time period. 
Candidates to start with could be IL-4 and CD40L (Banchereau 2015).  
Chemotherapy is a conventional treatment for cancer patients but can suppress the immune 
system as a side effect. This can lead to a destructive immuno-chemotherapy combination as 
chemotherapy can have harmful effect on immunotherapy if administered in a sensitive stage 
of in vivo lymphocyte activation and proliferation. On the contrary, we demonstrated that 
doxorubicin increases the antigen presenting ability of human B cells. There are also reports 
about improved survival time of patients who received both chemotherapy and immunotherapy 
(Zhong, Teng et al. 2011). We suggest an optimized plan for time and dose of drug 
administration, may improve combination of both treatments.  
As a next step, APCs isolated from patients treated with neoadjuvant chemotherapy should be 
treated with autologous tumor extract and co-cultured with CD4+ T cells from the same 
patients, to investigate tumor antigen presenting properties of the APCs. Cells from the patients 
with no chemotherapy treatment can be used for comparison. Furthermore, screening the 
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 immune cells with other chemotherapeutic drugs is necessary to have a more detailed scheme 
of the drugs with a positive effect on the immune system. To broaden this detailed scheme, 
other cell types should be studied. The effect of chemotherapeutic drugs on the tumor specific 
properties of cytotoxic T cells, regulatory T and B cells, natural killer (NK) cells and 
macrophages are highly important to investigate. Furthermore, studying different 
concentrations of the drugs with moderate effect on the immune cells may result in finding an 
optimized setup in which they can be more effective on the immune system. Finally, the 
mechanism with which the chemotherapeutic drugs enhance tumor antigen presenting ability 
of the APCs should be examined to increase the understanding of the drug properties.  
Among B cell subpopulations isolated from patients with solid malignancies, we found rare 
populations with dual light chains. A finding that contradicts the theory behind allelic 
exclusion. Interestingly, increased Ig κ+ Ig λ+ B cells proportions of CD19+ cells were detected 
in tumor and tumor associated lymph nodes, suggesting contribution of tumor environment in 
the increased emergence of the B cell subpopulation. To increase our understanding of B cells 
as APCs in the context mentioned immunotherapy, the role and function of Ig κ+ Ig λ+ B cells 
need to be studied further. Based on our study, we know that Ig κ+ Ig λ+ B cells isolated from 
tumor associated tissues, can be found among activated, as well as IgG+ B cells, suggesting 
tumor antigen engagement. Furthermore, we demonstrated lack of RAG II production and 
decreased levels of AID transcript in sentinel node isolated Ig κ+ Ig λ+ B cells in a UBC patient, 
which illustrates the inability of the dual receptor B cells to undergo somatic hypermutation 
and class switching. There are reports about Ig κ+ Ig λ+ B cells in mice, which possess one, self-
reactive and one non-autoreactive receptor, making the B cells partially autoreactive (Liu, 
Velez et al. 2005). In this case, B cells with dual receptors may not be very optimal in our 
immunotherapy setup and should be depleted in in vitro cultures. In addition, Ig κ+ Ig λ+ B cells 
with possible regulatory properties will not be responding in synergy with the desired effector 
B cells in our CD4+ T cell based adoptive immunotherapy.  
Thus, further studies are needed to dissect the role of Ig κ+ Ig λ+ B cells and their properties in 
cancer patients. The next step is to examine tumor antigen presenting characteristic of dual 
positive B cells in cancer patients, by sorting the cells and treating them with autologous tumor 
extract before co-culturing with CD4+ T cells as responder cells. B cells with single light chains 
can be used as control in this setup. In addition, the proportion of Ig κ+ Ig λ+ B cells in cancer 
patients with neoadjuvant chemotherapy should be compared with their counterparts in patients 
without chemotherapy to address the effect of chemotherapeutic drugs on the emergence of B 
cells with dual receptors. Additionally, mRNA screening of the Ig κ+ Ig λ+ B cells are needed 
to further understand their properties.  
 
 
  
28 
 6 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Kroppens immunförsvar består bland annat av vita blodkroppar som försvarar oss mot 
främmande mikroorganismer. De känner igen främmande strukturer som finns på ytan av bland 
annat virus, bakterier och parasiter. Immunförsvaret kan delas in i en medfödd och en adapativ 
del. Immunceller som hör till det medfödda immunförsvaret kan snabbt agera vid mot en 
inkräktare. De adaptiva immuncellerna tar längre tid på sig att reagera, men kan bilda så 
kallade, minnesceller och bidra till ett långvarigt, specifikt och starkt immunförsvar. 
Cancer bildas när fel uppstår i arvsanlaget (DNA) hos kroppens celler. Detta gör att de kan 
snabbt föröka sig och så småningom bilda tumör. Dessa celler kan i många fall uppvisa 
proteiner på sin yta som uppfattas av immuncellerna som främmande. Immuncellerna tar då 
hand om cancern hos friska människor. Cancercellerna kan dock i vissa fall lära sig att undgå 
kroppens immunförsvar genom att till exempel gömma de proteiner som uppfattats som 
främmande av immunförsvaret. Detta leder till tumörtillväxt och metastasering.  
Immunterapi handlar om att förstärka immunförsvaret så att tumörceller kan bli igenkända och 
eliminerade av de medfödda och adaptiva immuncellerna. Ett sätt, är att ta ut celler från 
patientvävnader som tagits vid operation och odla en variant av de adaptiva immuncellerna 
som kallas T celler. Man ser till att de blir fler och effektivare mot tumören innan de ges tillbaka 
till patienten via blodet.  
T cellers roll i kroppen är bland annat att producera signal-molekyler, så kallade cytokiner med 
vilka de kan leda och dirigera uppgifter till andra immunceller som i sin tur kan döda 
cancercellerna. För att en T cell ska kunna skicka tumörspecifika signaler till de andra 
immuncellerna, behöver den blir presenterad till främmande tumörämnen, så kallade 
tumörantigen. Det finns en del immunceller som tar upp och presenterar tumörspecifika 
proteiner till T cellerna. De kallas för antigenpresenterande celler. En av de 
antigenpresenterande cellerna kallas för B celler, som också hör till det adaptiva 
immunsystemet. 
Denna avhandling handlar om hur B celler påverkas av tumör men även av 
cytostatikabehandling hos cancer patienter. I det första arbetet studerade vi olika 
utvecklingsstadier av B celler i cancer patienter. Vi visade att fler B celler i sina aktiverade och 
mogna tillstånd existerade i tumör och metastaserade lymfkörtlar som tydde på att de 
genomgått en tumörspecifik respons. Vidare visade vi att en specifik B cell i tumören hade 
förökat sig, troligtvis på grund av att den hade hittat tumörantigen och visat det till T cellerna 
som in sin tur hade signalerat B cellerna att expandera. Vi drar slutsatsen att B celler hos 
cancerpatienter aktiveras mot deras tumör och troligtvis presenterar antigen till T cellerna.  
Cytostatika behandling är en terapi som ofta leder till cancer förstörelse men samtidigt kan 
också orsakar många biverkningar hos patienter. Bland annat är det allmänt accepterat att de 
försvagar immunförsvaret. I det andra arbetet utredde vi hur tre sedvanliga cytostatika som 
cancer patienter ofta får som behandling, nämligen cisplatin, doxorubicin och irinotecan, 
påverkar B celler. B celler isolerades från friska bloddonatorer och behandlades med 
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 ovannämnda cytostatika. Vi avslöjade att B celler, till skillnad mot den allmänna uppfattningen 
om cytostatika, blev mer aktiverade av doxorubicin. Vår studie framhävde även att 
antigenpresenterande förmågan av B celler som var behandlade med doxorubicin ökade. 
Vidare visade vi att B celler i blodet hos patienter med cancer i urinblåsan, som var behandlade 
med doxorubicin-innehållande cytostatikapaket, hade ökad antigenpresenterande förmåga. Vi 
drar slutsatsen att med rätt tids och dosplanering av cytostatika, kan både cytostatika 
behandling och immunterapi kombineras som en framtid strategi att behandla cancerpatienter.  
I flera studier har forskare visat att vita blodkroppar som finns in i tumörvävnaden, har stor 
positiv betydelse för patienternas överlevnad. I arbete III, rapporterar vi att B celler runtom 
tumör hos patienter med urinblåsecancer, bildar speciella strukturer tillsammans med T celler 
som visar täcken på ett samspel mellan dem i tumören. Vidare belyste vi att antal B/T 
cellstrukturer verkade ha en positiv verkan på patientprognosen. Cytokiner som nämndes ovan, 
produceras av immunceller för att väcka immunförsvaret. Det finns dock cytokiner som 
produceras för att hämma immunförsvaret. Detta är en funktion hos så kallade, regulatoriska 
immunceller, som skyddar kroppen från att ta skada av för stor aktivitet av immunförsvaret. En 
sådan cytokin kallas interleukin 10 (IL-10). IL-10 kan dock både hämma och stimulera 
immunförsvaret. Vi studerade även denna cytokin i tumören hos urinblåsecancer-patienterna. 
Vi såg att IL-10 som var producerat av regulatoriska B celler, hade en negativ inverkan på 
patienternas överlevnad medan IL-10 producerat av andra celler i tumören än B celler hade en 
positiv effekt. Vi drar slutsatsen att B celler i tumör är positivt för patientöverlevnaden men 
inte när de producerar IL-10. IL-10 producerat av andra celler är dock gynnsamt.  
B celler kan känna igen tumörantigen med hjälp av receptorer som finns på sina cellytan. Den 
allmänna uppfattningen är att när en B cell kommer ut från benmärgen har den endast en typ 
receptor, specifikt mot en enda antigen. I sista arbetet detekterade vi B celler med två olika 
receptorer på sin yta hos cancer patienter, nämligen Igκ och Igλ. Dessa B celler fanns i ökat 
antal i tumörassocierade lymfkörtlar jämfört med icke-tumörassocierade lymfkörtlar. Detta 
väckte misstanken att tumören och dess miljö orsakade deras uppkomst. Vi kunde påvisa att de 
fanns bland aktiverade B celler men hade inte förmågan att utvecklas vidare eller att bli 
effektivare mot tumörantigen. När vi odlade B celler i medium från en tumörcellslinje, ökade 
antalet B celler med dubbla receptorer. Vi drar slutsatsen att Igλ+ Igκ+ B celler samlas I 
tumörassocierande vävnader, troligtvis på grund av tumörmiljön. Mer forskning är nödvändigt 
för att förstå rollen av B celler med dubbla receptorer hos cancer patienter.  
Med denna avhandling har vi visat att B celler har stor potential att användas som 
antigenpresenterande celler i en T cellsbaserad immunterapi. Framtida projekt bör handla om 
hur man bäst kan optimera denna typ av immunterapi genom att odla B cellerna tillsammans 
med T cellerna för att förstärka patienterna immunförsvar.  
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